Mometasone

證據等級: L5

預測適應症: 1 個

Mometasone: From Topical/Nasal Corticosteroid Use to Primary Cutaneous T-Cell Lymphoma

One-Sentence Summary

Mometasone is a high-potency corticosteroid, commonly used topically and intranasally for inflammatory skin and airway conditions (specific approved indication text is not present in this dataset). The TxGNN model predicts it may be effective for Primary Cutaneous T-Cell Lymphoma, but this is currently supported only by 0 clinical trials and 2 case-report-level publications, with no mometasone-specific efficacy data.

Quick Overview

Item	Content
Original Indication	Not specified in dataset (mometasone is a topical/nasal corticosteroid class drug; typical uses are dermatitis/eczema and allergic rhinitis)
Predicted New Indication	Primary Cutaneous T-Cell Lymphoma
TxGNN Prediction Score	99.36%
Evidence Level	L4
Finland Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data for mometasone is not available. Based on known pharmacological information, mometasone is part of the high-potency corticosteroid class, and its anti-inflammatory/immunosuppressive efficacy in skin- and mucosa-related inflammatory conditions is well established.

Mechanistically, corticosteroids suppress cutaneous lymphocyte infiltration and reduce local cytokine release, which is the pharmacological basis for using topical steroids as skin-directed therapy in early-stage cutaneous T-cell lymphoma (CTCL)/mycosis fungoides. However, this is a class effect shared by all topical corticosteroids, not evidence specific to mometasone.

The TxGNN score of 99.36% likely reflects structural and mechanistic similarity inference within the corticosteroid class rather than direct clinical evidence for mometasone in CTCL. Both retrieved publications describe mometasone only as a background/failed treatment in case reports of related lymphoproliferative skin conditions (pseudolymphoma, mycosis fungoides), not as a studied intervention with efficacy outcomes — so the prediction should be treated as a research hypothesis rather than a validated repurposing signal.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

PMID	Year	Type	Journal	Key Findings
40821495	2025	Case Report	Proceedings (Baylor University Medical Center)	Case of refractory cutaneous pseudolymphoma (T-cell lymphoproliferative process mimicking CTCL); mometasone and tacrolimus were tried but unsuccessful before switching to tapinarof
25442255	2015	Case Report	Journal of Cutaneous Pathology	Pediatric case of CD8+CD56+ cytotoxic mycosis fungoides (a primary cutaneous T-cell lymphoma subtype); mometasone mentioned in the clinical context of the disease, not as a proven therapeutic

Finland Market Information

Mometasone currently has no marketing authorization in Finland (0 licenses on record).

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: Evidence is limited to two case reports in which mometasone appears only as a background or failed treatment, with no clinical trials, no drug-specific efficacy data, and a blocking data gap on TFDA/package-insert safety information — this falls short of what is needed even for a preliminary safety review (S1).

To proceed, the following is needed:

TFDA/manufacturer package insert with warnings and contraindications (currently blocking S1 safety review)
Confirmed mechanism of action (MOA) data from DrugBank or primary literature
Confirmed original approved indication(s) for mometasone
Clinical or preclinical studies evaluating mometasone specifically (not corticosteroids as a class) in CTCL/mycosis fungoides
Drug interaction (DDI) data, currently unavailable
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.